CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab

J. J. Ifthikharuddin, L. A. Mieles, Joseph D Rosenblatt, C. K. Ryan, D. M. Sahasrabudhe

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)171-173
Number of pages3
JournalAmerican Journal of Hematology
Volume65
Issue number2
DOIs
StatePublished - Oct 5 2000
Externally publishedYes

Fingerprint

CD Antigens
Lymphoproliferative Disorders
Bone Marrow Transplantation
Immunotherapy
B-Lymphocytes
Transplants
Antigens
Neoplasms
Therapeutics
Rituximab

Keywords

  • CD-20
  • Post-transplant lymphoproliferative disorder
  • PTLD
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

CD-20 expression in post-transplant lymphoproliferative disorders : Treatment with rituximab. / Ifthikharuddin, J. J.; Mieles, L. A.; Rosenblatt, Joseph D; Ryan, C. K.; Sahasrabudhe, D. M.

In: American Journal of Hematology, Vol. 65, No. 2, 05.10.2000, p. 171-173.

Research output: Contribution to journalArticle

Ifthikharuddin, J. J. ; Mieles, L. A. ; Rosenblatt, Joseph D ; Ryan, C. K. ; Sahasrabudhe, D. M. / CD-20 expression in post-transplant lymphoproliferative disorders : Treatment with rituximab. In: American Journal of Hematology. 2000 ; Vol. 65, No. 2. pp. 171-173.
@article{3ce4836ab91940988905d6e69cbe853d,
title = "CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab",
abstract = "B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment. (C) 2000 Wiley-Liss, Inc.",
keywords = "CD-20, Post-transplant lymphoproliferative disorder, PTLD, Rituximab",
author = "Ifthikharuddin, {J. J.} and Mieles, {L. A.} and Rosenblatt, {Joseph D} and Ryan, {C. K.} and Sahasrabudhe, {D. M.}",
year = "2000",
month = "10",
day = "5",
doi = "10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z",
language = "English",
volume = "65",
pages = "171--173",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - CD-20 expression in post-transplant lymphoproliferative disorders

T2 - Treatment with rituximab

AU - Ifthikharuddin, J. J.

AU - Mieles, L. A.

AU - Rosenblatt, Joseph D

AU - Ryan, C. K.

AU - Sahasrabudhe, D. M.

PY - 2000/10/5

Y1 - 2000/10/5

N2 - B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment. (C) 2000 Wiley-Liss, Inc.

AB - B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment. (C) 2000 Wiley-Liss, Inc.

KW - CD-20

KW - Post-transplant lymphoproliferative disorder

KW - PTLD

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=0033828581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033828581&partnerID=8YFLogxK

U2 - 10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z

DO - 10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z

M3 - Article

C2 - 10996837

AN - SCOPUS:0033828581

VL - 65

SP - 171

EP - 173

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -